Caracterización de eventos adversos a hidroxicloroquina, ivermectina, azitromicina y tocilizumab en pacientes hospitalizados por COVID-19 en un hospital del Seguro Social de Salud del Perú

Rodríguez Tanta, L. Yesenia; Cachay Rojas, Enrique; Fiestas Saldarriaga, Fabián; Alva Lozada, Guisela; Fernández-Rojas, Paola; Delgado Escalante, Ruth Raquel.
Rev. peru. med. exp. salud publica ; 40(1): 16-24, ene. 2023. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-1442115

Documentos relacionados

  1. Characterization of adverse events to hydroxychloroquine, ivermectin, azithromycin and tocilizumab in patients hospitalized due to COVID-19 in a Peruvian Social Health Insurance hospital.
  2. [Trends in drugs usage for COVID-19 during the first wave of the pandemic in a hospital in Lima, Peru].
  3. Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies.
  4. Safety profile of COVID-19 drugs in a real clinical setting.
  5. Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021.
  6. Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype.
  7. Multidrug treatment for COVID-19.
  8. Seguridad de abatacept en pacientes con artritis reumatoidea
  9. Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia.
  10. Sales of "COVID kit" drugs and adverse drug reactions reported by the Brazilian Health Regulatory Agency